188 related articles for article (PubMed ID: 37335139)
1. Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma.
Davidson G; Helleux A; Vano YA; Lindner V; Fattori A; Cerciat M; Elaidi RT; Verkarre V; Sun CM; Chevreau C; Bennamoun M; Lang H; Tricard T; Fridman WH; Sautes-Fridman C; Su X; Plassard D; Keime C; Thibault-Carpentier C; Barthelemy P; Oudard SM; Davidson I; Malouf GG
Cancer Res; 2023 Sep; 83(17):2952-2969. PubMed ID: 37335139
[TBL] [Abstract][Full Text] [Related]
2. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
3. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
4. Pyroptosis-Related Subtypes Predict the Response of Clear Cell Renal Cell Carcinoma to Targeted Therapy.
Ma J; Kang Z; Yang G; Wang X; Si M; Wang Y; Li G; Bai S; Zeng F; Li M; Wang Z; Wang L; Xu W
Front Biosci (Landmark Ed); 2023 Dec; 28(12):334. PubMed ID: 38179741
[TBL] [Abstract][Full Text] [Related]
5. Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.
Lu X; Vano YA; Su X; Helleux A; Lindner V; Mouawad R; Spano JP; Rouprêt M; Compérat E; Verkarre V; Sun CM; Bennamoun M; Lang H; Barthelemy P; Cheng W; Xu L; Davidson I; Yan F; Fridman WH; Sautes-Fridman C; Oudard S; Malouf GG
Cell Rep Med; 2023 Nov; 4(11):101287. PubMed ID: 37967556
[TBL] [Abstract][Full Text] [Related]
6. An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.
Lu X; Vano Y; Helleux A; Su X; Lindner V; Davidson G; Mouawad R; Spano JP; Rouprêt M; Elaidi R; Compérat E; Verkarre V; Sun C; Chevreau C; Bennamoun M; Lang H; Tricard T; Cheng W; Xu L; Davidson I; Yan F; Fridman WH; Sautes-Fridman C; Oudard S; Malouf GG
Clin Cancer Res; 2023 Apr; 29(7):1279-1291. PubMed ID: 36374555
[TBL] [Abstract][Full Text] [Related]
7. Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.
Jiang W; Zeng H; Liu Z; Jin K; Hu B; Chang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Apr; 40(4):166.e15-166.e25. PubMed ID: 34998671
[TBL] [Abstract][Full Text] [Related]
8. Decoding the Immune Microenvironment of Clear Cell Renal Cell Carcinoma by Single-Cell Profiling to Aid Immunotherapy.
Liu J; Xu J; Zhang T; Xu K; Bao P; Zhang Z; Xue K; He R; Ma L; Wang Y
Front Immunol; 2022; 13():791158. PubMed ID: 35812372
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma.
Zhang ZC; Liu YF; Xi P; Nie YC; Sun T; Gong BB
Hereditas; 2023 Jan; 160(1):1. PubMed ID: 36635779
[TBL] [Abstract][Full Text] [Related]
10. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
[TBL] [Abstract][Full Text] [Related]
11. Integrative Analysis of the Genomic and Immune Microenvironment Characteristics Associated With Clear Cell Renal Cell Carcinoma Progression: Implications for Prognosis and Immunotherapy.
Lin E; Zhu P; Ye C; Huang M; Liu X; Tian K; Tang Y; Zeng J; Cheng S; Liu J; Liu Y; Yu Y
Front Immunol; 2022; 13():830220. PubMed ID: 35677048
[TBL] [Abstract][Full Text] [Related]
12. Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma.
Xu C; Li Y; Su W; Wang Z; Ma Z; Zhou L; Zhou Y; Chen J; Jiang M; Liu M
Aging (Albany NY); 2022 Sep; 14(17):6917-6935. PubMed ID: 36057262
[TBL] [Abstract][Full Text] [Related]
13. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma.
Zhang D; Ni Y; Wang Y; Feng J; Zhuang N; Li J; Liu L; Shen W; Zheng J; Zheng W; Qian C; Shan J; Zhou Z
J Transl Med; 2023 Jul; 21(1):489. PubMed ID: 37474942
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
Front Immunol; 2022; 13():934243. PubMed ID: 36189255
[TBL] [Abstract][Full Text] [Related]
15. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
Front Immunol; 2022; 13():890150. PubMed ID: 35686121
[TBL] [Abstract][Full Text] [Related]
16. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.
Chen M; Nie Z; Huang D; Gao Y; Cao H; Zheng L; Zhang S
Front Immunol; 2022; 13():1048204. PubMed ID: 36505496
[TBL] [Abstract][Full Text] [Related]
17. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.
Lin E; Liu X; Liu Y; Zhang Z; Xie L; Tian K; Liu J; Yu Y
Front Immunol; 2021; 12():653358. PubMed ID: 33746989
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti-angiogenic therapy.
Ambrosetti D; Coutts M; Paoli C; Durand M; Borchiellini D; Montemagno C; Rastoin O; Borderie A; Grepin R; Rioux-Leclercq N; Bernhard JC; Pagès G; Dufies M
BJU Int; 2022 Jan; 129(1):80-92. PubMed ID: 34107167
[TBL] [Abstract][Full Text] [Related]
19. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma.
Xu H; Xu WH; Ren F; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
Aging (Albany NY); 2020 Jan; 12(1):866-883. PubMed ID: 31915310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]